David Risinger
Stock Analyst at Leerink Partners
(2.64)
# 679
Out of 5,354 analysts
197
Total ratings
59.30%
Success rate
31.08%
Average return
Main Sectors:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
JNJ Johnson & Johnson | Downgrades: Market Perform | 169 153 | 153.87 | -0.57% | 4 | May 13, 2025 | |
VRTX Vertex Pharmaceutica... | Downgrades: Market Perform | 550 503 | 446.54 | 12.64% | 4 | May 6, 2025 | |
REGN Regeneron Pharmaceut... | Upgrades: Outperform | 762 834 | 484.03 | 72.3% | 8 | Feb 5, 2025 | |
ABBV AbbVie | Upgrades: Outperform | 206 | 188.08 | 9.53% | 7 | Nov 22, 2024 | |
BMY Bristol-Myers Squibb | Upgrades: Outperform | 55 73 | 48.12 | 51.7% | 4 | Nov 12, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 49 69 | 22.95 | 200.65% | 2 | Nov 11, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 5.68 | 181.69% | 1 | Oct 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 44 | n/a | n/a | 2 | Sep 17, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 106 153 | 34.27 | 346.45% | 2 | Sep 3, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 15 10 | 11.03 | -9.34% | 3 | Aug 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 28 2 | 1.97 | 1.52% | 2 | Jul 9, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 47 | 21.52 | 118.4% | 1 | Apr 16, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 267 318 | 287.7 | 10.53% | 4 | Oct 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 6 11 | 12.93 | -14.93% | 2 | Aug 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 410 458 | 766.71 | -40.26% | 16 | May 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 42 | 53.95 | -22.15% | 3 | Mar 16, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 81 91 | 108.99 | -16.51% | 3 | Feb 3, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 49 48 | 23.39 | 105.22% | 14 | Feb 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 8 10 | 11.31 | -11.58% | 4 | Dec 19, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 88 117 | n/a | n/a | 12 | Dec 13, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 7 10 | 29.64 | -66.26% | 2 | Jun 24, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 35 37 | 9.53 | 288.25% | 2 | Feb 22, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 162 176 | 110.07 | 59.9% | 3 | Apr 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 16 | 8.65 | 84.97% | 1 | Mar 10, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 53 45 | 26.34 | 70.84% | 7 | Mar 5, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 5 7 | n/a | n/a | 8 | Mar 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 22 35 | 4.65 | 652.69% | 4 | Feb 26, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 41 | 13.46 | 204.61% | 5 | Nov 24, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 167 174 | 168.5 | 3.26% | 9 | Nov 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 51 | 33.52 | 52.15% | 1 | Jul 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 13 8 | 17.5 | -54.29% | 14 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 23 18 | n/a | n/a | 12 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 89 | 78.41 | 13.51% | 8 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 16 | 31.25 | -48.8% | 6 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 5 3 | 7.29 | -58.85% | 4 | Apr 2, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 156 | n/a | n/a | 8 | Jan 30, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 14 35 | n/a | n/a | 5 | Aug 17, 2018 |